A detailed history of Schonfeld Strategic Advisors LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 22,227 shares of IMVT stock, worth $611,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,227
Holding current value
$611,464
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $557,897 - $702,595
22,227 New
22,227 $586,000
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $252,944 - $423,058
17,813 Added 47.3%
55,475 $1.05 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $979,158 - $1.26 Million
-64,123 Reduced 63.0%
37,662 $584,000
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $103,061 - $277,592
-15,639 Reduced 13.32%
101,785 $1.81 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $461,476 - $747,990
117,424 New
117,424 $656,000
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $178,852 - $227,408
-24,400 Closed
0 $0
Q3 2021

Nov 16, 2021

SELL
$7.01 - $11.37 $179,456 - $291,072
-25,600 Reduced 51.2%
24,400 $212,000
Q2 2021

Aug 16, 2021

SELL
$9.4 - $16.85 $49,848 - $89,355
-5,303 Reduced 9.59%
50,000 $528,000
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $479,695 - $1.82 Million
36,674 Added 196.87%
55,303 $887,000
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $955,649 - $1.39 Million
-26,283 Reduced 58.52%
18,629 $860,000
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $237,676 - $408,916
10,512 Added 30.56%
44,912 $2,000
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $477,128 - $978,336
34,400 New
34,400 $837,000
Q1 2020

May 15, 2020

SELL
$8.36 - $17.13 $710,600 - $1.46 Million
-85,000 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$10.02 - $16.4 $851,700 - $1.39 Million
85,000 New
85,000 $1.35 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.